Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betula populifolia pollen is a non-standardized allergenic extract derived from the gray birch tree. It is utilized as a diagnostic tool for skin testing to identify patients with birch pollen hypersensitivity and as a therapeutic agent in allergen immunotherapy (hyposensitization). In immunotherapy, the extract is administered in gradually increasing doses to induce immunological tolerance, typically characterized by a shift from a Th2-mediated allergic response to a Th1 or T-regulatory cell response and a reduction in allergen-specific IgE-mediated mast cell activation. It is regulated in the United States as a biologic under a Biologic License Application (BLA) and is often used in combination with other birch species extracts in clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betula populifolia pollen.